Individualizing Neo/Adjuvant Treatment in Early Breast Cancer Care: Education, Tools, and Resources for Patients and Providers

Download All
Review the latest evidence-based strategies on individualized early breast cancer treatment with expert commentaries, online modules, downloadable slidesets, and an Interactive Decision Support Tool that provides personalized management recommendations for treatment selection in early breast cancer.
Yara Abdou, MD

Downloadable Slidesets

This slideset offers an overview of current risk assessment and biomarker testing used to inform treatment decisions and predict treatment response and prognosis in patients with HER2-negative early breast cancer.

Yara Abdou, MD Released: April 6, 2022

This slideset accompanies an expert analysis of the role of Ki-67 in risk assessment and discusses recently approved adjuvant abemaciclib for patients with HR-positive, HER2-negative EBC at high risk of recurrence.

Yara Abdou, MD Released: May 12, 2022

Downloadable slideset describing germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.

Yara Abdou, MD Released: May 17, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings